Recuperative herbal formula Jing Si maintains vasculature permeability balance, regulates inflammation and assuages concomitants of "Long-Covid"

Biomed Pharmacother. 2023 Jul:163:114752. doi: 10.1016/j.biopha.2023.114752. Epub 2023 Apr 26.

Abstract

Coronavirus disease 2019 (COVID-19) is a worldwide health threat that has long-term effects on the patients and there is currently no efficient cure prescribed for the treatment and the prolonging effects. Traditional Chinese medicines (TCMs) have been reported to exert therapeutic effect against COVID-19. In this study, the therapeutic effects of Jing Si herbal tea (JSHT) against COVID-19 infection and associated long-term effects were evaluated in different in vitro and in vivo models. The anti-inflammatory effects of JSHT were studied in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells and in Omicron pseudotyped virus-induced acute lung injury model. The effect of JSHT on cellular stress was determined in HK-2 proximal tubular cells and H9c2 cardiomyoblasts. The therapeutic benefits of JSHT on anhedonia and depression symptoms associated with long COVID were evaluated in mice models for unpredictable chronic mild stress (UCMS). JSHT inhibited the NF-ƙB activities, and significantly reduced LPS-induced expression of TNFα, COX-2, NLRP3 inflammasome, and HMGB1. JSHT was also found to significantly suppress the production of NO by reducing iNOS expression in LPS-stimulated RAW 264.7 cells. Further, the protective effects of JSHT on lung tissue were confirmed based on mitigation of lung injury, repression in TMRRSS2 and HMGB-1 expression and reduction of cytokine storm in the Omicron pseudotyped virus-induced acute lung injury model. JSHT treatment in UCMS models also relieved chronic stress and combated depression symptoms. The results therefore show that JSHT attenuates the cytokine storm by repressing NF-κB cascades and provides the protective functions against symptoms associated with long COVID-19 infection.

Keywords: Acute lung injury; Cytokine storm; Decoction; NF-ƙB; Respiratory disease; Severe COVID.

MeSH terms

  • Acute Lung Injury* / metabolism
  • Animals
  • COVID-19*
  • Cytokine Release Syndrome
  • Cytokines / metabolism
  • Humans
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Lipopolysaccharides / adverse effects
  • Mice
  • NF-kappa B / metabolism
  • Post-Acute COVID-19 Syndrome

Substances

  • Lipopolysaccharides
  • Cytokines
  • NF-kappa B